Research

Hormonal

GLP-1 receptor agonists (specifically liraglutide) induce significant weight loss and improve metabolic parameters (insulin sensitivity, testosterone) in obese women with PCOS, offering a therapeutic avenue for infertility associated with this condition.

For women with PCOS and obesity, GLP-1 receptor agonists like liraglutide (1.2-3.0 mg daily) are a clinically supported pharmacological option to induce weight loss and reduce testosterone levels when lifestyle changes alone have failed or are difficult to maintain. This intervention targets the underlying hormonal and metabolic drivers of infertility.

GoodSupportsHIGH confidence
The weight loss effects of GLP-1RA offer a unique opportunity to expand the treatment options available to PCOS patients. Several studies demonstrated significant weight loss and testosterone reduction, with mixed results relative to improvements in insulin resistance parameters and menstrual patterns.
Hellas Cena et al. · The Journal of Clinical Endocrinology & Metabolism · 2020

Why this rating

Based on a narrative review of multiple randomized controlled trials and meta-analyses.

Source

Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists

Hellas Cena et al. · The Journal of Clinical Endocrinology & Metabolism · 2020

DOI 10.1210/clinem/dgaa285

narrative_reviewCited 332×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →